Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus Pembrolizumab in Advanced HCC Post-PD1/PD-L1
NCT04696055Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoint: Overall Response Rate up to 38 months. Started Feb 2021; status: completed.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04696055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696055.